Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors. Additional preclinical programs under the BDC umbrella target other tumor antigens and immune checkpoints, aiming to broaden Bolt’s pipeline across multiple cancer types.
Founded in 2015 and headquartered in Cambridge, Massachusetts, Bolt Biotherapeutics completed its initial public offering in August 2019 and trades on the Nasdaq under the symbol BOLT. The company has established research collaborations and material-transfer agreements with academic institutions and industry partners to support the advancement of its BDC candidates. By delivering innate immune stimulators directly to the tumor site, Bolt seeks to enhance antitumor efficacy while minimizing systemic toxicity commonly associated with broader immune-activating agents.
While Bolt’s operations are based in the United States, the company maintains a global outlook through its international clinical trial network and potential strategic partnerships for development and commercialization. The management team is led by President and Chief Executive Officer Anna Protopapas, Ph.D., who brings over two decades of experience in oncology drug development. Supporting her are executives with deep expertise in clinical operations, regulatory affairs and business development, all aligned to advance Bolt’s immuno-oncology pipeline from early-stage studies toward later-phase trials.
With its differentiated BDC approach, Bolt Biotherapeutics aims to generate proof-of-concept data that could support combination strategies with existing checkpoint inhibitors or other targeted therapies. The company’s focus on localized activation of innate immunity positions it to explore a range of hematologic and solid tumor indications, underscoring its ambition to deliver next-generation immunotherapies that offer improved safety and efficacy profiles.
AI Generated. May Contain Errors.
